Stockreport

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Neuphoria Therapeutics Inc.  (NEUP) 
PDF Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Ca [Read more]